Oruka Therapeutics’ Promising Long-Term Strategy and Advancements in Psoriasis Treatments ...
Jefferies analyst Michael Yee has maintained their bullish stance on ORKA stock, giving a Buy rating today.Don't Miss our Black Friday ...
Strong Prescription Growth and Competitive Advantage Drive Buy Rating for Arcutis ...
Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...
BioPharma Dive15 小时
J&J pill clears skin in two late-stage psoriasis studies
The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...
manilatimes17 小时
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of ...
Additionally, it can also be caused by multiple rounds of chemotherapy, and depression treatment drugs. The spleen is essential for filtering blood, supporting immune function, and managing red blood ...
pharmaphorum21 小时
J&J plots filings after psoriasis drug clears phase 3 test
Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...
The Sun21 小时
The causes of maddening ‘winter itch’ and 5 ways to avoid getting it
"This is because skin conditions like eczema and psoriasis often need targeted treatments to avoid flare-ups and soothe irritation. "Dermatologists may recommend prescription medication such as ...